Gene therapy trial targets HIV and lymphoma together
NCT ID NCT03593187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new gene therapy in 2 HIV-positive people with high-risk lymphoma. The therapy involved taking their own stem cells and immune cells, adding a gene to block HIV, and giving them back after chemotherapy. The main goal was to see if the procedure was safe and if the modified cells could survive in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Saint Louis
Paris, 75475, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo